.png)
Biotech Bulls & Breakthroughs
Welcome to Biotech Bulls & Breakthroughs! This brand new podcast from BioPharmCatalyst explores the dynamic world of biotech investing alongside long-time biotech trader Sheff from Sheff Station. Each month, we will be discussing current events in the biotech industry and how these events impact investors, as well as a discussion of upcoming catalysts in the biotech space.
Biotech Bulls & Breakthroughs
Latest Episodes
Biotech Stocks Catalyst to Watch Fall 2026: The Surprising Impact of FDA Adcom Meetings
In this episode, John Gagliano and Sheff Sheffield unlock hidden strategies behind biotech success, from FDA decision dynamics to the most promising upcoming catalysts; they reveal how savvy investors spot opportunities before the crowd c...
.png)
Middle to 3Q 2026 Biotech Catalyst: FDA Policy Shifts and Their Impact on Biotech Stocks
In this episode, John Gagliano and Sheff Sheffield discuss recent developments in biotech, including FDA policy shifts, key catalysts for upcoming biotech stocks, and market trends amidst frothy conditions. Essential insights for investors look...
The Hidden Power of One Pivotal Trial That Changed FDA’s Game | Biotech Bulls & Breakthroughs
In this episode, John Gagliano and Sheff Sheffield unpack the game-changing FDA decision that could add millions to Outlook Therapeutics’ valuation overnight. You'll discover how a small biotech overcame years of setbacks, clinched a pivotal FD...
Biotech Investing: Biotech Mid 2026 Catalysts To Watch
In this episode, as the biotech earnings season continues, John Gagliano and Sheff Sheffield explore the resilience of the biotech market, the impact of FDA policies, and the significance of conferences like AACR and ASCO. They highlight the po...
The Future of Biomanufacturing | Michael Heltzen, eXoZymes
In this episode of Biotech Bulls & Breakthroughs, John sits down with Michael Heltzen, CEO of exoZymes, to discuss the revolutionary move toward cell-free biomanufacturing. Discover how exoZymes is using AI to bypass the limitations of livi...
